XCXianwen Cheng

Xianwen Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xianwen Cheng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A clinical study of non-bioartificial liver DPMAES support system in hepatitis B-related acute-on-chronic liver failure

    by Xianwen Cheng, Yanrong Zhan, YaoShun Liu, Xia Zeng, Zhendong Wang, Feng Wang, Ya Mao, Song Na

    This study aims to observe the clinical efficacy of the dual plasma molecular adsorption exchange system (DPMAES) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), with a focus on its regulatory effect on cytokine storm. A total of 60 HBV-ACLF patients were enrolled in this study. The observation group, comprising 30 patients, received DPMAES treatment, while the control group underwent PE treatment. We compared the efficacy changes between the two groups post-treatment. A total of 55 HBV-ACLF patients who completed the study were analyzed, Patients treated with DPMAES showed significant improvements in clinical outcomes. After DPMAES treatment, HBV-ACLF patients exhibited notably 90 day survival rate increased by 18% compared to those in the PE group. Moreover, total bilirubin levels decreased markedly, albumin and platelet levels increased compared to the PE group. After DPMAES treatment, the patient showed a significant decrease in inflammatory cytokine IL-6 (t = 5.046, P < 0.001) and a significant decrease in procalcitonin (t = 4.66, P < 0.001). DPMAES was more effective than PE in rapidly reducing TBiL, improving coagulation function and mitigating cytokine storm. It maintained platelet stability more effectively while minimizing albumin consumption to a greater extent, significantly improved 90-day survival. Trial registration: Chinese Clinical Trial Registry, ChiCTR2300076117.


  • Open Access

    A single-center experience of non-bioartificial DFAPP support systems among Chinese patients with hyperlipidemic moderate/severe acute pancreatitis

    by Xianwen Cheng, Yanrong Zhan, Zhendong Wang, Feng Wang, Xia Zeng, Ya Mao, YaoShun Liu

    To assess the clinical efficacy of Double Filtration Plasmapheresis (DFAPP), a novel blood purification method, in treating hyperlipidemic moderate/severe pancreatitis (HL-M/SAP). A total of 68 HL-M/SAP patients were enrolled in this study. The observation group, comprising 34 patients, received DFAPP treatment, while the control group underwent CVVH + PA treatment. We compared the efficacy changes between the two groups post-treatment. Patients treated with DFAPP showed significant improvements in clinical outcomes. After 72 h of DFAPP treatment, HL-M/SAP patients exhibited notably lower multiple organ failure scores and a reduced mortality rate compared to those in the CVVH + PA group. Triglyceride levels in HL-M/SAP patients treated with DFAPP for 48 h averaged 3.75 ± 1.95, significantly lower than the 9.57 ± 3.84 levels in the CVVH + PA group (P < 0.05). Moreover, CRP levels decreased markedly, IL-17 levels diminished, IL-10 levels increased, and the decline in IL-35 levels was significantly less pronounced compared to the CVVH + PA group. The recurrence rate of pancreatitis was also significantly lower after 6 months. The early implementation of DFAPP in HL-M/SAP patients effectively reduces triglyceride levels, suppresses pro-inflammatory factors, enhances anti-inflammatory factors, and mitigates cytokine storm-induced sepsis damage. Consequently, this leads to a decrease in the incidence of multiple organ failure, improved patient survival rates, and a reduce the recurrence rate of lipogenic pancreatitis.Trial registration: Chinese Clinical Trial Registry, ChiCTR2300076066.


  • Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis

    by Yanrong Zhan, Xianwen Cheng, Pingping Mei, Jiyun Wu, Yan Ou, Yaping Cui

    This study aims to assess the risk of colorectal stricture progressing to colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD). The literature from PubMed, Embase, Web of Science, and Cochrane Library databases was searched from the date of databases’ creation to 5 November 2022. The Newcastle-Ottawa Scale was used to evaluate the quality of the included literature. Meta-analysis was conducted using the Stata 15 software and R 4.04 software. Two case-control studies and 12 cohort studies were eventually included. Colorectal stricture in patients with IBD increased the risk of progressing to CRN [odds ratio (OR): 1.52, 95% confidence interval (CI): 1.02–2.29, P = 0.042], but was irrelevant to the risk of progressing to ACRN (OR: 3.56, 95% CI 0.56–22.70, P = 0.180). The risk of CRN were further distinguished in patients with ulcerative colitis (UC) and Crohn’s disease (CD) Our findings showed that colorectal stricture may increase the risk of progressing to CRN in patients with UC (OR = 3.53, 95%CI 1.62–7.68, P = 0.001), but was irrelevant to the risk of progressing to CRN in patients with CD (OR = 1.09, 95% CI 0.54–2.21, P = 0.811). In conclusion, colorectal stricture in patients with IBD can be used as a risk factor for predicting CRN but cannot be used as a risk factor for predicting ACRN. Stricture is a risk factor for CRN in patients with UC but not in patients with CD. More prospective, multi-center studies with large samples are expected to confirm our findings.


  • Open Access

    A meta analysis of TCM syndrome differentiation and treatment combined with biofeedback in the treatment of functional constipation

    by Yanrong Zhan, Xianwen Cheng, Lianhui Liu, Yaping Cui, Jiyun Wu, Yu Zhao

    Objective: To systematically evaluate the efficacy of TCM syndrome differentiation and treatment combined with biofeedback in the treatment of functional constipation. Methods: All the clinical randomized controlled trials (RCTs) of TCM syndrome differentiation and treatment combined with biofeedback in the treatment of functional constipation, which were published in September 2022, were retrieved by computer from CNKI, VIP, Wanfang, The Cochrane Library, Pubmed and Embase and other databases. Use RevMan5.3 software for meta analysis. Results: Totally 937 patients were included in 16 clinical randomized controlled trials. Meta analysis showed that traditional Chinese medicine based on syndrome differentiation and treatment combined with biofeedback treatment for functional constipation had more advantages than conventional biofeedback treatment in terms of effective rate (RR=1.21, 95% CI (1.13, 1.30), Z=5.61, P<0.0001) and improvement of constipation symptom score (SMD=-0.31, 95% CI (-0.53, -0.10), Z=2.82, P=0.005), and the negative rate was higher in balloon ejection test (RR=1.26, 95% CI (1.05, 1.50), Z=2.48, P=0.01), It plays a role in reducing anal systolic pressure (MD=15.56, 95% CI (8.59, 22.53), Z=4.38, P<0.0001), but it has no statistical significance in reducing anal resting pressure (MD=-1.25, 95% CI (-15.75, 13.25), Z=0.17, P=0.87), It also played a very good role in reducing anxiety score (MD=-5.04, 95% CI (-7.16, -2.92), Z=4.66, P<0.00001) and depression score (MD=-5.85, 95% CI (-7.93, -3.77), Z=5.52, P<0.00001), and had a greater advantage in reducing follow-up recurrence rate (RR=0.39, 95% CI (0.25, 0.60), Z=4.27, P<0.0001). In terms of adverse reactions, there was no significant difference between the treatment group and the observation group (P=1.00). Conclusion: TCM syndrome differentiation and treatment combined with biofeedback has more advantages than conventional biofeedback treatment.